Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) hit a new 52-week low during mid-day trading on Monday. The company traded as low as GBX 28 and last traded at GBX 29.83, with a volume of 64,571 shares traded. The stock had previously closed at GBX 29.90.
Faron Pharmaceuticals Oy Trading Down 0.2%
The company has a current ratio of 2.40, a quick ratio of 1.09 and a debt-to-equity ratio of 154.15. The stock has a 50-day simple moving average of GBX 35.09 and a 200 day simple moving average of GBX 50.86. The company has a market cap of £60.52 million, a price-to-earnings ratio of -2.59 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
